Hope Rugo· @hoperugo · X·· 21 小时前评分70
正文 · 机器翻译
Binghe Xu 介绍了中国 Healer 试验的数据。该试验评估 anbenitamab（双特异性 HER2ab）联合脂质体多西他赛与 THP 相比用于 HER2+ MBC 的疗效，结果显示 PFS 显著改善，血液学毒性小幅增加。脂质体多西他赛已在美国获批。今天发表于 NEJM！ #ESMO2026 @OncoAlert
72 浏览 · 4 赞 · 3 转发 · 1 回复
会议摘要
LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.org帖内回复
- Hope Rugo@hoperugo
Interesting to consider how this fits into the ADC TDXd world.
来源：Hope Rugo · x.com